SEB Asset Management AB »

Halozyme Therapeutics shares owned by SEB Asset Management AB

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by SEB Asset Management AB from 13F filings

Historical chart of SEB Asset Management AB investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by SEB Asset Management AB consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by SEB Asset Management AB

Quarter filed Position value Share count Share price at filing
2026-06-30 $5.9M 75k 78.27
2026-03-31 $2.2M 35k 64.63

More positions owned by SEB Asset Management AB

NVIDIA Corporation (NVDA)
Apple (AAPL)
Astrazeneca Ord (AZN)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Micron Technology (MU)
Eli Lilly & Co. (LLY)
Meta Platforms Cl A (META)
Advanced Micro Devices (AMD)
JPMorgan Chase & Co. (JPM)
Johnson & Johnson (JNJ)
Applied Materials (AMAT)

View all positions for SEB Asset Management AB

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Capital Management
Vanguard Portfolio Management
State Street Corporation
Invesco
Robeco Investment Management
Bank of America Corporation
Morgan Stanley
Geode Capital Management
William Blair Investment Management
Snyder Capital Management
Dimensional Fund Advisors
D. E. Shaw & Co
Thomas Stevens, CFA"
Royal London Asset Management

View all funds holding Halozyme Therapeutics